PMCBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends April 30

PharmaCyte Biotech, Inc.

Financials through Q1 FY2027, quarter ended Jul 31, 2026Last filing: 10-Q on Sep 14, 2026

$0.34+0.00 (+0.53%)

Close on Oct 19, 2026

Market cap: $3.67M
P/E (TTM): –
Dividend yield: –

PharmaCyte Biotech, Inc. income statement

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2026 2026-04-30	FY 2025 2025-04-30	FY 2024 2024-04-30	FY 2023 2023-04-30	FY 2022 2022-04-30	FY 2021 2021-04-30	FY 2020 2020-04-30	FY 2019 2019-04-30	FY 2018 2018-04-30	FY 2017 2017-04-30	FY 2016 2016-04-30	FY 2015 2015-04-30	FY 2014 2014-04-30	FY 2013 2013-04-30	FY 2012 2012-04-30	FY 2011 2011-04-30
Revenue	0	0	0	0	0	0	0	0	0	0	0	0	0	0.01	0.07	0.13
Cost of Revenue	–	–	–	–	–	–	–	–	–	–	0	0	0	0.01	0.02	0.03
Gross Profit	–	–	–	–	–	–	–	–	–	–	0	0	0	0.00	0.05	0.09
Research & Development	0.39	0.44	0.41	0.47	0.69	0.92	0.30	0.46	2.00	1.18	1.41	3.48	0.32	0	–	–
Selling, General & Admin	–	–	–	–	–	–	–	–	–	–	2.29	2.39	2.79	0.72	0.43	0.25
Selling & Marketing	–	–	–	–	–	–	–	–	–	–	0	0.23	0.87	0.11	0.01	0.01
General & Administrative	4.91	3.94	6.11	1.11	1.09	0.42	1.16	1.38	1.82	0.74	2.29	2.16	1.92	0.62	0.42	0.24
Operating Expenses	6.85	4.38	8.52	6.46	4.39	3.62	3.83	4.10	6.98	4.44	6.07	13	19	1.69	2.00	0.48
Operating Income	-6.85	-4.38	-8.52	-6.46	-4.39	-3.62	-3.83	-4.10	-6.98	-4.44	-6.07	-13	-19	-1.68	-1.95	–
Interest Expense	–	–	–	0	0.00	0.00	0.00	0	0	0.00	0.00	0.00	0.02	0.15	0.23	0.17
Interest & Investment Income	0.73	1.42	3.40	1.94	0.16	0	–	–	–	–	–	–	–	–	–	–
Other Non-Operating Income	-13	35	8.85	2.14	0.15	0.07	0.00	0.03	0.15	0.00	0.01	3.33	-8.27	0.09	0.05	–
Asset Impairment Charges	–	–	–	0	0	0	0	0	0	0	0	0	0	–	–	–
Gain (Loss) on Sale of Assets	–	0	-1.57	0	–	–	–	–	–	–	–	–	–	0	-0.08	–
Income Tax Expense	0	0	0	0	0	0	0	0	0	0	0	0	0	0	–	–
Income from Continuing Operations	–	–	–	–	–	–	–	–	–	–	–	–	–	–	-1.95	-0.39
Net Income	-19	31	0.33	-4.32	-4.24	-3.55	-3.83	-4.07	-6.83	-4.44	-6.06	-9.93	-27	-1.60	-1.90	-1.40
Preferred Dividends	0.28	1.13	2.52	0	–	–	–	–	–	–	–	–	–	–	–	–
Net Income to Common	-23	23	-17	-4.32	–	–	–	–	–	–	–	–	–	–	–	–
EPS (Basic)(per share)	-2.77	3.19	-1.80	-0.22	-0.27	-2.45	-4.23	0.00	-15.00	-15.00	-15.00	-15.00	-75.00	0.00	-15.00	0.00
EPS (Diluted)(per share)	-2.77	3.19	-1.80	-0.22	-0.27	-2.45	-4.23	0.00	-15.00	-15.00	-15.00	-15.00	-75.00	0.00	–	–
Shares Outstanding (Basic, Weighted)(shares)	8.38	7.33	9.58	19	16	1.45	0.90	0.73	0.65	0.56	0.50	0.47	0.39	0.29	0.25	0.23
Shares Outstanding (Diluted, Weighted)(shares)	8.38	7.33	9.58	19	16	1.45	0.90	0.73	0.65	0.56	0.50	0.47	0.39	0.29	0.25	0.23
EBITDA	–	–	–	–	–	–	–	–	–	–	–	–	–	-1.68	-1.92	–

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jul 31, 2026

Profitability, TTM

Gross margin: –
Operating margin: –
Net margin: –
Return on equity, FY2026: -45.6%

Financial strength

Current ratio: 40.30
Debt to equity: –
Debt to assets: –
Cash to current liabilities: 2307.7%

Valuation

P/E ratio: –
Price to sales: –
Price to book: 0.13
Dividend yield: –